Hudson Bay Capital Management
ATRA icon

Hudson Bay Capital Management’s Atara Biotherapeutics ATRA Stock Holding History

Hudson Bay Capital Management’s Portfolio ATRA Stock Details ATRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-1,000
Closed -$453K – 766
2017
Q4 		$453K Buy
+1,000
New +$369K 0.01% 437
2017
Q3 		– Sell
-400
Closed -$140K – 385
2017
Q2 		$140K Buy
+400
New +$154K ﹤0.01% 490

Other funds holding ATRA

Baupost Group
Baupost Group Boston, Massachusetts $5.42B AUM 22.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BM
Bridger Management New York $150M AUM 17.71% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Hudson Bay Capital Management's ATRA Position: Q1 2018 in Review

Hudson Bay Capital Management sold out of Atara Biotherapeutics (ATRA) in Q1 2018, closing a stake of 1,000 shares — an estimated $453K sold.

Hudson Bay Capital Management first reported a position in ATRA in Q2 2017 and held it in 2 quarters. The position peaked at $453K in Q4 2017. 114 funds tracked by Wall St. Rank hold ATRA as of Q1 2018.

  • Hudson Bay Capital Management reported no remaining Atara Biotherapeutics position as of Q1 2018 after selling out during the quarter.
  • Hudson Bay Capital Management sold 1,000 Atara Biotherapeutics shares in Q1 2018, an estimated $453K.
  • Hudson Bay Capital Management first reported a position in Atara Biotherapeutics in Q2 2017 and held it in 2 quarters.
  • Hudson Bay Capital Management's Atara Biotherapeutics position peaked at $453K in Q4 2017.
  • 114 funds tracked by Wall St. Rank held Atara Biotherapeutics as of Q1 2018.

Based on Hudson Bay Capital Management's 13F filing for Q1 2018, filed 14 May 2018.